Skip to content
Eternygen GmbH
  • ABOUT US
    • TEAM
    • BOARD
    • OBSERVERS
    • ADVISORS
  • SCIENCE
    • R&D
    • LITERATURE & PAPERS
  • NEWS
    • PRESS & NEWS
    • FOUNDERS IN THE NEWS
  • CONTACT
  • DE / EN

Author: eternygenFlorian

20/09/202320/09/2023

July 2023 – Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity

founders in news - en by eternygenFlorian0 comments
Eternygen´s founder Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity. (in German) Find the video here.
Read more>>
19/09/202319/09/2023

August 2023 – Eternygen published new data: citrate transporter INDY/NaCT/SLC13A5 as a therapeutic target for kidney diseases

press statement - en by eternygenFlorian0 comments
In collaboration with Dipender Gill and Stephen Burgess, we've identified a noteworthy new connection between hepatic INDY/SLC13A5 and kidney function. This [...]
Read more>>
19/09/2023

August 2023 – Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep

press statement - en by eternygenFlorian0 comments
Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep [...]
Read more>>
08/09/202320/09/2023

July 2023 – Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity

press statement - en by eternygenFlorian0 comments
Eternygen´s founder Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity. (in German) Find the video here.
Read more>>
08/09/202308/09/2023

March 2023 – Eternygen at BioEuropeSpring conference

press statement - en by eternygenFlorian0 comments
Meet Eternygen at BioEuropeSpring conference in Basel from 20-22 March 2023 More information here.
Read more>>
08/09/2023

October 2022 – Eternygen at BioEurope conference

press statement - en by eternygenFlorian0 comments
Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022 More information here.
Read more>>
08/09/202320/09/2023

September 2022 – Grit Zahn presents at TESS Research Foundation’s International Research Conference and biotx.ai in September

press statement - en by eternygenFlorian0 comments
Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation's International Research Conference in Vienna [...]
Read more>>
08/09/202320/09/2023

August 2022 – Eternygen at the “Aging research and drug discovery meeting” in Copenhagen

press statement - en by eternygenFlorian0 comments
Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from August 28th to 1 September. [...]
Read more>>
08/09/2023

August 2022 – Eternygen published new paper on SLC13A5 inhibitors

press statement - en by eternygenFlorian0 comments
Eternygen published new paper on SLC13A5 inhibitors titled: “A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis [...]
Read more>>
08/09/202308/09/2023

April 2022 – Andreas Birkenfeld and Dr. Grit Zahn are Guest editing a Special Issue on “I’m Not Dead Yet in Metabolic Regulation”

press statement - en by eternygenFlorian0 comments
Andreas Birkenfeld and Dr. Grit Zahn are Guest editing a Special Issue on “I'm Not Dead Yet in Metabolic Regulation” [...]
Read more>>
26/11/2021

November 2021 – Prof. Birkenfeld featured in german TV ZDF Series “Auf der Suche nach dem ewigen Leben”

founders in news - en by eternygenFlorian0 comments
Eternygen Co-Founder Andreas Birkenfeld is featured in the German TV ZDF Series "Auf der Suche nach dem ewigen Leben" and [...]
Read more>>
28/01/202126/11/2021

January 2021 – Prof. Birkenfeld publishes new paper regarding the role of mIndy/NaCT for blood pressure titled „The longevity gene mIndy (I’m Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms.”

founders in news - en by eternygenFlorian0 comments
Link to Paper Eternygen GmbH Press release Berlin, January 27, 2021 The longevity gene mINDY (I’m Not Dead, Yet) not [...]
Read more>>
26/10/202009/06/2021

October 2020 – Eternygen Announces the First Closing of its Series A2 Funding Round

press statement - en by eternygenFlorian0 comments

Eternygen Announces the First Closing of its Series A2 Funding Round

Read more>>
22/04/202009/06/2021

April 2020 – Eternygen is nominated for the “German Accelerator Life Sciences” programme

press statement - en by eternygenFlorian0 comments

News of Eternygen

Read more>>
22/04/202009/06/2021

April 2020 – Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020.

press statement - en by eternygenFlorian0 comments

Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020. Link

Read more>>
24/03/202009/06/2021

March 2020 – Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the Tess research foundation in March 2020.

press statement - en by eternygenFlorian0 comments

Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the […]

Read more>>
10/02/202009/06/2021

February 2020 – Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH

press statement - en by eternygenFlorian0 comments

Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH Press statement

Read more>>
09/01/202009/06/2021

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA

press statement - en by eternygenFlorian0 comments

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA Eternygen is attending the Biotech Showcase conference […]

Read more>>
07/01/202009/06/2021

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th 2019

press statement - en by eternygenFlorian0 comments

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th Eternygen will attend the BioEurope conference in Hamburg […]

Read more>>
03/01/202009/06/2021

Prof. Birkenfeld publishes new review on Transporters as Drug Targets titled „Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.”

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld publishes new review on Transporters as Drug Targets titled „Solute Carrier Transporters as Potential Targets for the Treatment […]

Read more>>
30/10/201909/06/2021

Prof. Birkenfeld publishes new review on NAFLD

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld publishes new review on NAFLD (Link to Paper)

Read more>>
01/10/201909/06/2021

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the University Clinic Tübingen

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the […]

Read more>>
30/03/201809/06/2021

Prof. Birkenfeld was awarded with the Abstract Award

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld was awarded with the Abstract Award Prof. Birkenfeld was awarded with the Abstract Award by the American College […]

Read more>>
13/01/201809/06/2021

Prof. Birkenfeld in Sächsische Zeitung

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld in Sächsische Zeitung Prof. Birkenfeld in Sächsische Zeitung with the topic “How your lifestyle advances diabetes”. (Article in […]

Read more>>
05/12/201709/06/2021

Prof. Birkenfeld publishes new INDY (I’m Not Dead Yet) review

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld publishes new INDY (I’m Not Dead Yet) review Prof. Birkenfeld publishes new INDY (I’m Not Dead Yet) review […]

Read more>>
20/11/201709/06/2021

Eternygen at BioFIT 2017

press statement - en by eternygenFlorian0 comments

Eternygen at BioFIT 2017 Eternygen was invited to join panel discussion at BioFIT 2017 conference “How are collaborations key to […]

Read more>>
20/10/201709/06/2021

Prof. Birkenfeld is chairman of the working group diabetes and heart

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld is chairman of the working group diabetes and heart Prof. Birkenfeld is the new chairman of the working […]

Read more>>
18/09/201709/06/2021

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

press statement - en by eternygenFlorian0 comments

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany) Press release

Read more>>
18/09/201709/06/2021

Prof. Birkenfeld visiting expert at MDR Sachsen radio

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld visiting expert at MDR Sachsen radio Prof. Birkenfeld visiting expert at MDR Sachsen radio talking about cholesterol (in German)

Read more>>
13/07/201709/06/2021

Prof. Birkenfeld in expert discussion with MDR1 radio

founders in news - en by eternygenFlorian0 comments

Prof. Birkenfeld in expert discussion with MDR1 radio Discussion about “Sugar as a drug” (in German)

Read more>>

Posts navigation

Older posts

Recent Posts

  • July 2023 – Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity
  • August 2023 – Eternygen published new data: citrate transporter INDY/NaCT/SLC13A5 as a therapeutic target for kidney diseases
  • August 2023 – Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep
  • July 2023 – Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity
  • March 2023 – Eternygen at BioEuropeSpring conference

Archives

  • September 2023
  • November 2021
  • January 2021
  • October 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • October 2019
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • January 2017
  • December 2016
  • June 2016
  • May 2016
  • March 2016
  • February 2016
  • May 2015
  • April 2015
  • February 2015
  • January 2015
  • September 2014
  • May 2014
  • September 2013
  • July 2013
  • December 2012
  • January 2011

Archives

  • September 2023
  • November 2021
  • January 2021
  • October 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • October 2019
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • January 2017
  • December 2016
  • June 2016
  • May 2016
  • March 2016
  • February 2016
  • May 2015
  • April 2015
  • February 2015
  • January 2015
  • September 2014
  • May 2014
  • September 2013
  • July 2013
  • December 2012
  • January 2011

Categories

  • founders in news – en
  • press statement – en

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • CONTACT
  • PRIVACY POLICY
  • IMPRINT
  • DeutschDeutsch
  • LinkedIn
eternygen GmbH 2023
We use cookies – including third-party cookies – to collect information about how visitors use our websites. They help us give you the best possible experience, continually improve our sites and provide you with offers that are tailored to your interests. The information collected via cookies can also be processed outside of the European Union, for example in the USA. By clicking the "Accept all" button you agree to the use of these cookies. Cookie settings Reject ACCEPT ALL
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT